The firm said that the RealTime CMV test is the only commercially available cytomegalovirus that can amplify two select regions of the CMV genome.

The kit was previously approved by FDA for use on Qiagen's Rotor-Gene Q real-time PCR platform, which is one component of the automated QiaSymphony platform.

It is the first FDA-approved test for the stem cell transplant use case and meets the WHO International Standard for comparable results.

Following a beta evaluation of the system, a virology lab in Sheffield, UK, ran a workflow assessment and found improvements with the system.

The DxN Veris was recently launched as a CE-marked product with a menu of viral load tests, and will launch in a few years in the US with STD and HAI assays. 

This Week in PNAS

In PNAS this week: human cytomegalovirus diversity, patterns of homologous recombination in E. coli, and more.

A team of researchers has characterized the genomic diversity of the human cytomegalovirus and uncovered potential therapeutic targets.

The German firm has signed a deal for BL&H to distribute, market, and sell its T-Track CMV kit in South Korea once it is approved as an in vitro diagnostic.

The firm is pursuing CE-IVD clearance of the new platform populated with a menu of its MGB assays.

The qPCR-based test for the Cobas 6800/8800 systems meets WHO standards and is available commercially in markets recognizing the CE mark. 


Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.